http://www.cancercompass.comCancerCompass is an online community committed to offering people living with cancer a place to receive cancer information and news, share knowledge, and share cancer treatment experiences. To learn more, visit our site today.en-us@copy; Copyright 2008, International Capital & Management Company, LLLP. All Rights Reserved.Tue, 07 Oct 2008 17:50:44 CDTTue, 07 Oct 2008 17:50:44 CDTCancercompass.com: hematological cancer60http://www.cancercompass.com/graphics/mini-logo.gifhttp://www.cancercompass.comhttp://www.cancercompass.com/cancer-news/1,14764,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14764,00.htm?rss=y In acute myeloid leukemias (AMLs), multidrug resistance (MDR) is frequently, but not always, caused by the MDR1 gene product, a 170- to 180-kDa glycoprotein known as P-glycoprotein (Pgp) or human MDRl protein (1). It is characterized by broad resistance to several structurally, chemically, and pharmacologically distinct chemotherapeutic compounds. Many theories explain how Pgp affects MDR, including the "drug pump" model, in which Pgp hydrolyzes adenosine triphosphate to actively pump drugs out of the cell (2,3). As many MDR cells have been found to have increased intracellular pH and decreased plasma membrane potentials, another explanation of the MDR mechanism of Pgp is the alteredpartition model. This model takes into account how the...Tue, 23 Sep 2008 00:00:00 CDThttp://www.cancercompass.com/cancer-news/1,14751,00.htm?rss=yhttp://www.cancercompass.com/cancer-news/1,14751,00.htm?rss=y Investigators publish new data in the report 'Development of minimal residual disease-directed therapy in acute myeloid leukemia.' According to recent research from Birmingham, the United Kingdom, "The last three decades have seen major advances in understanding the genetic basis of acute myeloid leukemia (AML). Comprehensive molecular and cytogenetic analysis can distinguish biologically and prognostically distinct disease subsets that demand differing treatment approaches." "Definition of these pretreatment characteristics coupled with morphological response to induction chemotherapy provides the framework for current risk-stratification schemes, aimed at identifying subgroups most (and least) likely to benefit from allogeneic transpla...Tue, 16 Sep 2008 00:00:00 CDT